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Context. Home care programs in Italy.
Objectives. The aim of this study was to assess a protocol for palliative sedation
(PS) performed at home.
Methods. A total of 219 patients were prospectively assessed to evaluate a PS
protocol in patients with advanced cancer followed at home by two home care
programs with different territorial facilities. The protocol was based on stepwise
administration of midazolam.
Results. A total of 176 of the patients died at home, and PS was performed in 24
of these patients (13.6%). Younger patients received the procedure more
frequently than older patients (P¼ 0.012). The principal reasons to start PS were
agitated delirium (n¼ 20) and dyspnea (n¼ 4). Mean duration of PS was
42.2 30.4 hours, and the mean doses of midazolam were 23e58 mg/day. Both
the home care team and the patients’ relatives expressed optimal or good levels of
satisfaction with the procedure in all but one case, respectively.
Conclusion. This protocol for PS was feasible and effective in minimizing
distress for a subgroup of patients who died at home. The characteristics of
patients who may be effectively sedated at home should be better explored in
future studies. J Pain Symptom Manage 2014;47:860e866.  2014 U.S. Cancer
Pain Relief Committee. Published by Elsevier Inc. All rights reserved.Key Words
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of life may experience intolerable suffering
refractory to targeted palliative therapies. As
death approaches, symptom control may be-
come more difficult and the goal of a peaceful
death may be unsuccessful. Palliative sedation
(PS) is considered to be an effective treatment
modality for dispelling refractory symptoms
when aggressive efforts fail to provide relief
in terminally ill patients with cancer.1,2 Accord-
ing to the definition proposed by the Euro-
pean Association for Palliative Care, PS is the
use of sedative medication to relieve intolera-
ble suffering in the last days of life.3 An even
more specific definition is the use of nonop-
ioid drugs to control refractory symptoms
in the dying. This palliative practice has
been used for years, with a variable incidence
ranging from 2% to 52%,4 depending on the
setting, population, cultural, ethnic and reli-
gious factors, institutional policies, or national
legislation rather than on appropriate and
timely decision making based on real patients’
needs.
Patients with cancer spend most of their
time at home, particularly in the last weeks of
life.5 Admission to hospital or staying at
home in last days of life depends on many dif-
ferent factors, including resource availability
and personal preference, other than clinical
needs.
PS can be performed at home. In a system-
atic review, the frequency of PS at home was
variable (13e35%), confirming data observed
in a previous survey of patient assessment in
the last days of life.6 In a previous retrospective
analysis of home care patients with cancer who
died at home, the frequency of PS was 13.2%.7
However, much information, including indica-
tions, mean duration, and drug used for PS,
was not available from the literature or clearly
structured, or no a priori definition of PS was
adopted.8 The large variability observed in
the use of PS among centers suggests a lack
of appropriate criteria adopted for the defini-
tion of PS.
The Home CaredItaly (HOCAI) group was
established with the intent of disseminating
and implementing the information gathered
on patients with cancer followed at home,
given the paucity of existing data in thisthe efficacy of a PS protocol, established by
the HOCAI group in a preliminary investigator
meeting, in a prospective study of patients with
advanced cancer followed at home. Secondary
aims included analysis of the characteristics of
these patients between two centers with differ-
ent territorial facilities, any problems encoun-
tered by the teams, and level of satisfaction
of the team and relatives.Methods
The study was conducted in two home palli-
ative care units (HPCUs) of the HOCAI group
that adhered to the protocol. The activities of
these units have been described elsewhere.6e8
The two HPCUs provide similar levels of assis-
tance, with visits ranging between two and
three a week for physicians, and three and
seven a week for nurses, in addition to provid-
ing on-call visits in case of need.6 Treatments
are based on local protocols aimed at control-
ling psychological and physical symptoms. Phy-
sicians, nurses, psychologists, physiotherapists,
and social workers are members of the multi-
disciplinary team, coordinated by a central
agency. Cases are discussed in a weekly meet-
ing or more often when necessary, with medi-
cal supervision. The teams receive continuous
education and have more than 5 years’ experi-
ence in home palliative care.
One of the teams participating in this study
is from L’Aquila, a mountain community with
one hospital with an acute oncology unit and
a palliative care service connected to a home
care program, providing continuity of care af-
ter discharge with the same health personnel.
The other is from Turin, a metropolitan area
with many oncology units and various pallia-
tive care services. The largest palliative care
service, FARO (Association for Assistance and
Research in Oncology), provides home care
and offers hospice admission. Patients are re-
ferred by different oncology units and then
can be followed at home or in hospice, accord-
ing to clinical and social needs.
The PS Protocol
The PS protocol was developed after some
preliminary meetings of HOCAI members
and updated after a series of conference calls,
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policies of each institution and supervision of
the group leader. All the patients who were ad-
mitted to the HPCUs in a six month period,
from July 2012 through December 2012, were
assessed. Patients who died at home during
this period were included in the study. In-
formed consent (by relatives) and ethics com-
mittee approval were obtained.
All the patients who were administered ‘‘spe-
cific sedatives to relieve intolerable suffering
from refractory symptoms by reducing a pa-
tient’s level of consciousness with nonopioid
sedative medication in the last days of life’’
were selected and considered as patients re-
ceiving PS, according to a definition shared
in a preliminary investigator meeting and
adopted in a previous retrospective study.7
The characteristics of this group of patients
were recorded on a structured sheet, as well
as the indication to start PS. Information re-
garding who proposed the start of PS was
recorded, and whether the patient or relatives
were involved in the decision and if there were
doubts or internal conflicts. Reasons for dis-
continuation of PS also were recorded.
After the decision to start PS was shared with
relatives, intravenous or subcutaneous mida-
zolam was started in doses of 20e30 mg/day,
independent from the previous use of sedative
or neuroleptic drugs. Opioids were main-
tained, if previously given for other reasons
(pain or dyspnea), via nonoral routes, with
no intention to sedate. If the physician judged
it appropriate, the second step was started,
increasing the dose of midazolam up to
30e60 mg/day. The third step was to use doses
higher than 60 mg/day. Other sedative drugs,
including neuroleptics, were allowed with
the third step, or continued if used before,
and dosages were used flexibly according to
the patients’ needs. Symptomatic agents, com-
monly used in the last days of life (e.g.,
diuretics and antisecretory agents), were ad-
ministered when necessary. Drugs and doses
were changed according to clinical need, with
no strict protocol.
Assessment
Pain, dyspnea, agitated delirium, and psy-
chological distress data, rated on a zero to 10
numerical scale, were collected at the begin-
ning of PS (T0) and then at one day intervalsuntil death (T1, T2, T3, and so on). Informa-
tion about drugs and doses used during PS
was recorded at the same times. Relatives
were asked about symptom intensity when
the patients were unable to provide this infor-
mation. The Communication Capacity Scale
and the Agitation Distress Scale also were
used to monitor the level and efficacy of PS.9
Finally, the level of satisfaction regarding the
efficacy of PS for home physicians and relatives
(optimal, good, fair, or poor) was recorded,
when available, within one week after the pa-
tient’s death.
Statistical Analysis
Data were collected and analyzed using SPSS
Software v. 14.0 (SPSS, Inc., Chicago, IL).
Descriptive summaries for all measures are
reported as means and standard deviations
for numeric variables, and as percentages
for categorical variables. Statistical analysis of
quantitative data, including descriptive statis-
tics, was performed for all the items. The
Chi-squared test was used to make compari-
sons with respect to categorical variables, and
Fisher’s exact test was used if sample size crite-
ria were not met for Chi-squared approxima-
tion. One-way analysis of variance was used
for parametric analysis. All P-values were two
sided, and P-values less than 0.05 were consid-
ered statistically significant.Results
A total of 219 patients were surveyed during
the study period, 117 and 102 in L’Aquila and
Turin, respectively. Mean age was 73.6 13
years, and 112 patients (51.1%) were male.
The mean Karnofsky Performance Status score
at the time of home care admission was
57.5 18.7. Primary cancer diagnoses were,
in rank order: gastrointestinal 47, urogenital
42, lung 36, liver 18, pancreas 18, head and
neck 16, hematologic tumor 16, breast 14,
and others 12. Survival from diagnosis was
810 1128 days. The mean time from diagno-
sis to beginning of home palliative care was
739 1099 days, and the mean interval from
starting home palliative care to death was
70 110 days. A total of 43 patients (19.3%)
did not die at home but were admitted to hos-
pital in the last days of life. No demographic
differences were found with other patients.
                      219 patients
                                               43 patients died in hospitals
                 176 patients died at home 
24 patients PS                           152 patients no PS 
Fig. 1. Flow chart of patients admitted to home
care. PS¼ palliative sedation.
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Fig. 1. The PS was performed in 24 of 176 pa-
tients who died at home (13.6%). The charac-
teristics of these patients are reported in
Table 1. The mean age of these 24 patients
was 67 19 years, and 10 (41.7%) were male.
The PS occurred more frequently in younger
patients (P¼ 0.012; analysis of variance test),
whereas no differences in gender were found
(P¼ 0.325; Chi-squared test).
The principal reasons to begin PS were agi-
tated delirium (n¼ 20) and dyspnea (n¼ 4).
At the time, the decision was made to begin
PS, the patients were not able to be involved
in the decision because of their clinicalTable 1
Characteristics of Patients
Age (y) Gender Diagnosis PS Indication Proposing
87 Female Brain Delirium Team-family
78 Male Lung Delirium Team-family
80 Male LMA Delirium Team
85 Female Parotid Delirium Team-family
70 Male Liver Delirium Team-family
72 Female Pancreas Delirium Team
54 Female Breast Delirium Team
24 Male LNH Delirium Team
86 Male Head-neck Dyspnea Team
60 Female Liver Delirium Team
45 Male Colon Delirium Team
66 Male Liver Delirium Team
73 Female Stomach Delirium Team
81 Male Prostate Delirium Team
79 Male Rectum Dyspnea Team
89 Female Colon Delirium Team
51 Female Colon Delirium Team
34 Female Liver Dyspnea Team-family
98 Female Ovarian Delirium Team
67 Male Colon Delirium Team-family
44 Female Sarcoma Dyspnea Team
62 Female Colon Delirium Team
79 Female Head-neck Delirium Team
54 Female Pancreas Delirium Team-family
PS¼ palliative sedation; LMA ¼ leukemia; LNH ¼ non-Hodgkin lymphoma.conditions. After starting PS, it was continued
until death; none of the patients’ relatives
asked for sedation to be discontinued. The
mean duration of PS was 42.2 30.4 hours.
Table 2 provides data on the mean daily doses
of opioids, sedatives, and symptomatic agents
used during PS in the 24 patients. In Table 3,
mean values of symptom intensity, Communi-
cation Capacity Scale scores, and Agitation Dis-
tress Scale scores are described. In most cases
after starting PS, pain was no longer evaluated
because of deep sedation or altered conscious-
ness. Other symptoms were based on the judg-
ment of proxies.
The level of satisfaction for the home care
team was optimal, good, and fair in 18, five,
and one case(s), respectively. The level of satis-
faction for relatives was optimal, good, and fair
in 15, eight, and one case(s), respectively. No
differences between home care team and rela-
tives were found (P¼ 0.261; Chi-squared test).Discussion
This is the first prospective study of PS per-
formed at home. The principal reason to be-
gin PS was agitated delirium, with dyspnea
being the second indication in about 20% ofWho Received PS
Duration (h) Team Satisfaction Family Satisfaction
72 Optimal Optimal
17 Optimal Optimal
8 Fair Optimal
96 Optimal Optimal
28 Optimal Optimal
27 Optimal Good
25 Optimal Optimal
36 Optimal Optimal
6 Optimal Optimal
45 Optimal Optimal
31 Optimal Optimal
53 Optimal Good
34 Good Optimal
94 Optimal Optimal
1 Optimal Good
82 Good Optimal
16 Optimal Good
26 Optimal Optimal
37 Optimal Good
100 Optimal Optimal
88 Good Good
34 Good Fair
14 Good Good
44 Optimal Good
Table 2
Drugs Used During Palliative Sedation
Drugs
T0 (N¼ 24) T1 (N¼ 20) T2 (N¼ 8) T3 (N¼ 6) T4 (N¼ 3)
n; mean (SD) daily dose, mg
Subcutaneous morphine 9; 86 (28) 8; 77 (38) 5; 78 (41) 4; 71 (44) 2; 75 (21)
Intravenous morphine 12; 168 (328) 11; 199 (354) 3; 490 (615) 2; 720 (678) 1; 240
Transdermal fentanyl, mg/h (SD) 3; 80 (45.8)
Midazolam 24; 27 (3.9) 20; 38 (17) 8; 56 (31) 6; 58 (36) 3; 53 (25)
Butylscopolamine 7; 88 (30) 8; 82 (25) 5; 84 (26) 4; 75 (30) 2; 60 (0.0)
Haloperidol 11; 9.4 (3.6) 9; 9.7 (2.5) 2; 12.5 (3.5) 2; 12.5 (3.5) 1; 10
Chlorpromazine 1; 200 1; 400 4; 225 (163) 3; 300 (141) 1; 400
Furosemide 0 2; 30 (14) 2; 30 (14) 1; 20 0
SD¼ standard deviation.
864 Vol. 47 No. 5 May 2014Mercadante et al.patients. This is in accordance with previous
retrospective studies performed at home
by our group and other authors,7,10,11 and in
contrast with older data.12,13 It is likely that
a modern approach and greater opioid avail-
ability make pain an infrequent indication
for PS. Younger patients were more frequently
sedated before death. Possibly, younger pa-
tients may be more aggressively treated and
may present more complex clinical situations
in the last days of life.8 Of interest, the decision
to begin PS was proposed by the home pallia-
tive care team on the basis of clinical need.
However, relatives shared this decision, and
no conflicts emerged, as demonstrated by the
absence of discontinuation of PS by request
of relatives. From a clinical standpoint, discon-
tinuation was unlikely to maintain an accept-
able level of symptom control. Generally,
information about patients’ or relatives’ re-
quests is poor and unclear, given the retrospec-
tive nature of most studies performed at home;
and that, in the Italian culture, advance direc-
tives are seldom provided, although in a Span-
ish study the decision to start PS was made withTable 3
Parameters Recorded During PS at
Parameters
T0 (N¼ 24) T1 (N¼ 2
Mean (SD) Mean (SD
Pain 1.7 (2.4) NV
Delirium (24 patients) 5.9 (3.4) 1.4 (2.2
Delirium (20 patientsa) 6.9 (2.7) 1.6 (2.3
Dyspnea (24 patients) 2.9 (4.0) 0.7 (1.9
Dyspnea (4 patientsa) 9.3 (0.9) 0.0 (0.0
Communication Capacity Scale 12.3 (3.2) 16.4 (0.7
Agitation Distress Scale 9.7 (4.8) 2.4 (3.3
Death rattle 0.3 (0.8) 0.5 (0.9
PS¼ palliative sedation; SD¼ standard deviation; NV ¼ non-evaluable.
aMean data for patients who were sedated only for delirium (20 patients) anthe patient in 45% of the cases.14 In previous
studies performed at home, no clear docu-
mentation has been reported regarding the
involvement in the decision-making process
immediately before starting PS. Circumstances
in which the decision has been made may be
different: whether PS was planned ahead or
was needed urgently, whether the preferences
of the dying patient were known, or whether
the emotional difficulties encountered in con-
trolling the patient’s symptoms during the last
days of life were components in the decision to
sedate the patient. The onset of PS often corre-
sponds to a moment in which the patient is no
longer collaborating.8 Indeed, consent and
decision to start PS have a different meaning,
and patients are unlikely to provide or share
a decision because of cognitive impairment
(delirium) or severe suffering (dyspnea). It is
reasonable that the clinical need to start
PS be proposed by an expert team, explaining
to family members the further steps and the
possible options of intervention, unless there
is an advance directive provided by the patient.
This finding is unlikely in the Mediterraneanthe T0eT4 Time Intervals
0) T2 (N¼ 8) T3 (N¼ 6) T4 (N¼ 3)
) Mean (SD) Mean (SD) Mean (SD)
NV NV NV
) 0.6 (1.7) 0 0
) 0.7 (1.9) 0 0
) 0 0 0
) 0 0 0
) 16.6 (0.7) 16.7 (0.8) 17
) 1.1 (1.6) 0.5 (0.6) 1
) 0.9 (1.3) 0.5 (1.2) 1 (1)
d for dyspnea (4 patients).
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and/or a higher level of confidence in health
professionals.15
The PS was highly effective, as confirmed by
the progressive decrease of symptom intensity,
although at this stage most symptoms were in-
directly evaluated by relatives, and could not
be expressed through verbal report by the pa-
tient. Satisfaction with PS was quite high, and
considered good or optimal in almost all cases
by both professionals and relatives.
According to the protocol, a stepwise ap-
proach was used, starting with midazolam.
Doses of midazolam were slightly increased
24 hours after starting PS, according to the
clinical needs and the level of unconsciousness
necessary to control symptoms. Then, a small
number of patients who survived more than
24 hours required further dose increments,
with an escalation index of about one in the
three patients who survived four days, with
doses even lower than those reported in other
studies.11 Of interest, the use of midazolam
out of hospital, subcutaneously or intrave-
nously, is off-label, although both home care
programs have direct contact with hospitals
or hospices and drugs are provided by these
institutions.
To monitor the effectiveness of PS, validated
tools were used.9 The Agitation Distress Scale
score progressively decreased immediately af-
ter starting PS. Similarly, the Communication
Capacity Scale, which demonstrated impaired
communication before starting PS, reached al-
most the maximum score (no communication
at all) subsequently.
A high proportion of patients died at home.
These data are quite impressive in comparison
with data reported in the literature. Specialized
home care has been shown to be associated
with reduced inpatient deaths and overall hos-
pitalization over the last two months of life in
comparison with patients living in areas devoid
of home palliative care services.14 In compari-
son with areas with no palliative care services,
hospital death frequency was lower (61%) in
the palliative home care areas. The findings
of this study show that most patients could
die at home; about 13% of them required PS
according to an a priori definition and using
a specific protocol. It would be interesting to
know the pathways of the 43 patients (about
20%) admitted to home care programs, whodid not die at home and were admitted to hos-
pital. Unfortunately, this information was un-
available. This aspect should be evaluated in
future studies.
Mean survival from the start of PS was rela-
tively short, less than two days, confirming pre-
vious observations and that patients were really
at the end of life.8 Of interest, it also was ob-
served that survival from the start of palliative
care was even longer in patients who were se-
dated. This finding potentially confirms the
beneficial role of PS performed at home, with-
out interfering or anticipating death, as repor-
ted in other settings.16,17 However, as in many
other studies, the group that did not require
PS had varying end-of-life trajectories and
survival estimates must consider many other
factors.
Death rattle frequently occurs in the dying
patient, occurring in 23e92%. Death rattle re-
sults from an accumulation of secretions in
the pharynx and/or airways in the absence of
effective reflexes for swallowing and cough-
ing.18 This may more frequently occur in pa-
tients with a low level of consciousness such
as sedated patients. In this study, where death
rattle was prospectively assessed and treated ac-
cording to a determined protocol, death rattle
intensity was relatively low, confirming that
careful monitoring and adequate treatment
may be successful, even at home.
A limitation of this study, which may affect
the results, concerns the design, which is that
of a prospective cohort study. As a conse-
quence, the statistical results may not always
be reliable, especially without a large sample
size because of the inability to ensure that
study groups are truly comparable at baseline.
In fact, without true randomization at base-
line, it is unlikely that differences in the
comparison groups can be controlled for effec-
tively. However, we must consider the difficulty
in carrying out this kind of study under ideal
conditions given the critically ill patients in-
volved. The results of this study, however,
may be useful in terms of the clinical manage-
ment of PS.
In conclusion, PS performed at home is
a feasible and effective method to relieve in-
tractable symptoms in the last days of life. It
would be interesting to evaluate the possible
differences existing among different home
care systems, hospices, or acute palliative care
866 Vol. 47 No. 5 May 2014Mercadante et al.units. Finally, more information should be
gathered on the specific services provided by
the local network of palliative care.Disclosures and Acknowledgments
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